What is the Cost of Diagnosis and Management of Drug Resistant Tuberculosis in South Africa?

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Pooran, Anil ^a   Pieterson, Elize ^a   Davids, Malika ^a   Theron, Grant ^a   Dheda, Keertan ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE; TUBERCULOSTATIC AGENT;

ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MEGADOSE; DRUG RESISTANT TUBERCULOSIS; DRUG SENSITIVE TUBERCULOSIS; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITALIZATION; HUMAN; LABORATORY TEST; LUNG RESECTION; PRACTICE GUIDELINE; SHORT COURSE THERAPY; SOUTH AFRICA; THORAX RADIOGRAPHY; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; DISEASE MANAGEMENT; DRUG COSTS; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MYCOBACTERIUM TUBERCULOSIS; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84872577328     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054587     Document Type: Article

References (44)

1. World Health Organization (2011) WHO Report 2011: Global Tuberculosis Control. (2011) Available: http://www.who.int/tb/publications/global_report/en/. Accessed 2012 Oct 20.
2. United Nations (2011) The UN Millenium Development Goals Report 2011 (2011) Available: www.un.org/millenniumgoals/reports.shtml.Accessed 2012 Mar.
3. Dheda K, Migliori GB, (2012) The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue? Lancet 379: 773-775.
4. Dheda K, Warren RM, Zumla A, Grobusch MP, (2010) Extensively drug-resistant tuberculosis: epidemiology and management challenges. Infect Dis Clin North Am 24: 705-725.
5. South African Department of Health (2011) Management of Drug-Resistant Tuberculosis: Policy Guidelines (2011) Available: www.kznhealth.gov.za/pharmacy/ptc/MDR2011.pdf.Accessed 2012 Oct 3.
6. Dheda K, Shean K, Zumla A, Badri M, Streicher EM, et al. (2010) Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. The Lancet 375: 1798-1807.
7. Kvasnovsky CL, Cegielski JP, Erasmus R, Siwisa NO, Thomas K, et al. (2011) Extensively Drug-Resistant TB in Eastern Cape, South Africa: High Mortality in HIV-Negative and HIV-Positive Patients. J Acquir Immune Defic Syndr 57: 146-152.
8. O'Donnell MR, Padayatchi N, Master I, Osburn G, Horsburgh CR, (2009) Improved early results for patients with extensively drug resistant tuberculosis and HIV in South Africa. Int J Tuberc Lung Dis 13: 855-861.
9. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB, (2010) Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 51: 6-14.
10. World Health Organization (2011) Tuberculosis Country Profiles: South Africa (2011) Available: http://www.who.int/tb/country/data/profiles/en/index.html.Accessed 2012 Jul.
11. Meyer-Rath G, Schnippel K, Long L, MacLeod W, Sanne I, et al. (2012) The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One 7: e36966.
12. Oxlade O, Falzon D, Menzies D, (2012) The Impact and Cost-effectiveness of Strategies to Detect Drug Resistant Tuberculosis. Eur Respir J 39: 626-634.
13. Resch SC, Salomon JA, Murray M, Weinstein MC, (2006) Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med 3: e241.
14. Suarez PG, Floyd K, Portocarrero J, Alarcon E, Rapiti E, et al. (2002) Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 359: 1980-1989.
15. Tupasi TE, Gupta R, Quelapio MID, Orillaza RB, Mira NR, et al. (2006) Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med 3: e352.
16. White VLC, Moore-Gillon J, (2000) Resource implications of patients with multidrug resistant tuberculosis. Thorax 55: 962.
17. Fitzpatrick C, Floyd K, (2012) A Systematic Review of the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant Tuberculosis. Pharmacoeconomics 30: 63-80.
18. Statistics South Africa (2012) Statistical Release P0141- Consumer Price Index August 2012 (2012) Available: http://www.statssa.gov.za/publications/P0141/P0141August2012.pdf.Accessed 2012 Oct 22.
19. United Nations (2011) Operational Rates of Exchange. (2011) Available: http://treasury.un.org. Accessed 2011 Dec.
20. Brust JCM, Lygizos M, Chaiyachati K, Scott M, van der Merwe TL, et al. (2011) Culture Conversion Among HIV Co-Infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South Africa. PloS one 6: e15841.
21. Calver AD, Murray M, Strauss OJ, Streicher EM, Hanekom M, et al. (2010) Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis 16: 264-271.
22. Farley JE, Ram M, Pan W, Waldman S, Cassell GH, et al. (2011) Outcomes of Multi-Drug Resistant Tuberculosis (MDR-TB) among a Cohort of South African Patients with High HIV Prevalence. PloS one 6: e20436.
23. Heller T, Lessells RJ, Wallrauch CG, Barnighausen T, Cooke GS, et al. (2010) Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 14: 420-426.
24. Iddriss A, Reddy D, Padayatchi N, Reddi A (2011) Pulmonary resection for extensively drug-resistant tuberculosis in Durban, South Africa. Joint Meeting of 19th ASCVTS and 21st ATCSA. Phuket, Thailand.
25. Mehta U, Durrheim DN, Blockman M, Kredo T, Gounden R, et al. (2008) Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. Br J Clin Pharmacol 65: 396-406.
26. Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov AD, et al. (2004) Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 8: 1382-1384.
27. Schaaf HS, Moll AP, Dheda K (2009) Multidrug-and extensively drug-resistant tuberculosis in Africa and South America: epidemiology, diagnosis and management in adults and children. Clin Chest Med 30: 667-683, vii-viii.
28. Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, et al. (2009) Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PloS one 4: e7186.
29. Shean KP, Willcox PA, Siwendu SN, Laserson KF, Gross L, et al. (2008) Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 19922002. Int J Tuberc Lung Dis 12: 1182-1189.
30. Sotgiu G, Ferrara G, Matteelli A, Richardson MD, Centis R, et al. (2009) Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 33: 871-881.
31. World Health Organization (2002) Guidelines for cost and cost-effectiveness analysis of tuberculosis control. (2002) Available: http://whqlibdoc.who.int/hq/2002/WHO_CDS_TB_2002.305b.pdf. Accessed 2012 Jun 18.
32. Cleary SM, McIntyre D, Boulle AM, (2006) The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa-a primary data analysis. Cost Eff Resour Alloc 4: 20.
33. World Health Organization (2011) Rapid Implementation of the Xpert MTB/RIF diagnostic test (2011) Available: http://whqlibdoc.who.int/publications/2011/9789241501569_eng.pdf.Accessed 2012 Oct 22.
34. South African Department of Health (2009) National Tuberculosis Management Guidelines (2009) Available: http://familymedicine.ukzn.ac.za/Libraries/Guidelines_Protocols/TB_Guidelines_2009.sflb.ashx.Accessed 2012 Aug 12.
35. World Health Organization (2006) Guidelines for the programmatic management of drug-resistant tuberculosis. (2006) Available: http://www.who.int/tb/challenges/mdr/programmatic_guidelines_for_mdrtb/en/index.html. Accessed 2012 Oct 21.
36. Suh DC, Woodall BS, Shin SK, Hermes-De Santis ER, (2000) Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother 34: 1373-1379.
37. Arbex MA, Varella Mde C, Siqueira HR, Mello FA, (2010) Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs. J Bras Pneumol 36: 641-656.
38. Schwartzman K, Menzies D, (2000) Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis. Am J Respir Crit Care Med 161: 780-789.
39. Pooran A, Booth H, Miller RF, Scott G, Badri M, et al. (2010) Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulm Med 10: 7.
40. Global Issues Health: High Drug Prices Hamper Drug-Resistant TB Treatment (2011) Available: http://www.globalissues.org/news/2011/06/17/10134.Accessed 2011 Apr.
41. Theron G, Peter J, van Zyl-Smit R, Mishra H, Streicher E, et al. (2011) Evaluation of the Xpert (R) MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 184: 132-140.
42. Basu S, Andrews JR, Poolman EM, Gandhi NR, Shah NS, et al. (2007) Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. The Lancet 370: 1500-1507.
43. World Health Organization (2005) Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti- Tuberculosis Drug Resistance Surveillance. Report no. 3. Prev-alence and trends. WHO/HTM/TB/2004.343. Geneva, Switzer-land (2005).
44. South African Department of Health. Tuberculosis Strategic Plan for South Africa, 2007-2011. Available: http://www.info.gov.za/view/DownloadFileAction?id=72544. Accessed 2012 Apr 10.